MedTrace Logo

The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions

NCT01368627 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1274

Last updated 2012-08-23

No results posted yet for this study

Summary

E-SERIES Registry evaluate the procedural and clinical outcomes of the Supralimus® SES in the treatment of unselected, high risk patients having coronary Artery blockage in the real world clinical practice.

Conditions

Interventions

DEVICE

Supralimus® Sirolimus-Eluting Coronary Stent

Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2

Sponsors & Collaborators

  • Cardiovascular Research Center, Brazil

    collaborator OTHER

  • Sahajanand Medical Technologies Limited

    lead INDUSTRY

Principal Investigators

  • Alexandre Abizaid,, MD · Instituto Dante Pazzanese de Cardiologia São Paulo, SP, Brazil

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368627 on ClinicalTrials.gov